Astra Cuts Price Of Losec In Sweden
Astra of Sweden has cut the price of its leading antiulcerant Losec (omeprazole) in its domestic market, which led to a decline in the firm's share price of 13 Swedish kroner on April 10 to 292 kroner ($43.97).
The price cut in Sweden is not a significant event, according to Astra's Steffan Ternby. He told the Marketletter that the firm has adjusted the price for the smallest pack size of Losec in Sweden, and that the overall price adjustment effect is below 5%.
The decision to reduce Losec's price was prompted by talks around the issue initiated by the Swedish drug pricing authorities. Mr Ternby said with Losec being the biggest-selling drug in Sweden and still rising, the product plays an important part in the Swedish drug bill.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze